CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Supernus Pharmaceuticals Inc - SUPN CFD

31.75
0.87%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024818 %
Charges from full value of position ($-0.25)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024818%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002596 %
Charges from full value of position ($0.03)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.002596%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 32.03
Open 31.82
1-Year Change 12.04%
Day's Range 31.75 - 32.11
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 19, 2024 32.03 1.04 3.36% 30.99 32.10 30.95
Sep 18, 2024 31.79 0.28 0.89% 31.51 32.51 31.51
Sep 17, 2024 31.67 0.27 0.86% 31.40 31.87 31.40
Sep 16, 2024 31.43 0.36 1.16% 31.07 31.65 30.63
Sep 13, 2024 31.03 -0.02 -0.06% 31.05 31.43 30.77
Sep 12, 2024 30.83 -0.22 -0.71% 31.05 31.51 30.42
Sep 11, 2024 31.04 -1.31 -4.05% 32.35 32.35 29.45
Sep 10, 2024 33.43 0.30 0.91% 33.13 34.04 33.13
Sep 9, 2024 33.86 0.77 2.33% 33.09 34.20 33.09
Sep 6, 2024 33.79 0.15 0.45% 33.64 34.40 33.50
Sep 5, 2024 34.32 0.88 2.63% 33.44 35.10 33.44
Sep 4, 2024 34.93 0.70 2.04% 34.23 34.95 34.20
Sep 3, 2024 34.65 0.43 1.26% 34.22 34.78 33.92
Aug 30, 2024 35.08 0.28 0.80% 34.80 35.11 34.16
Aug 29, 2024 34.91 0.29 0.84% 34.62 35.02 34.53
Aug 28, 2024 34.58 0.17 0.49% 34.41 34.74 34.27
Aug 27, 2024 34.83 0.20 0.58% 34.63 34.87 34.46
Aug 26, 2024 34.83 -0.11 -0.31% 34.94 35.34 34.64
Aug 23, 2024 34.93 0.50 1.45% 34.43 34.96 34.14
Aug 22, 2024 34.38 0.41 1.21% 33.97 34.64 33.97

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Supernus Company profile

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Supernus Pharmaceuticals Inc revenues increased 12% to $420.7M. Net income decreased 47% to $51M. Revenues reflect Net product sales- Trokendi XR segment increase of 34% to $231.5M, Net product sales-APOKYN segment increase of 70% to $73.3M. Net income was offset by Selling/General/Admin. Expense increase of 47% to $131.4M (expense), Advertising Expense increase of 58% to $59.7M (expense).

Equity composition

Common Stock $0.001 Par, 5/12, 62M auth., 23,912,319 issd. Insiders own approx. 6.73%. IPO:TBA

Industry: Proprietary & Advanced Pharmaceuticals

9715 Key West Avenue
ROCKVILLE
MARYLAND 20850
US

News

RBA Preview: Rates to remain unchanged with inflation-fighting still the focus

RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.

12:27, 20 September 2024

BoE Preview: no change expected but forward guidance will be key

The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.

14:53, 19 September 2024

FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion

Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.

11:30, 19 September 2024

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

People also watch

BTC/USD

63,171.95 Price
+0.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,622.64 Price
+1.370% 1D Chg, %
Long position overnight fee -0.0181%
Short position overnight fee 0.0099%
Overnight fee time 21:00 (UTC)
Spread 0.60

XRP/USD

0.59 Price
-1.060% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Oil - Crude

71.23 Price
+0.130% 1D Chg, %
Long position overnight fee 0.0269%
Short position overnight fee -0.0488%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 640,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading